BioCentury | Jan 14, 2013
Company News

Insight Genetics, Qiagen deal

Insight granted Qiagen exclusive, worldwide rights to ret proto-oncogene (RET) , c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) and DEP domain containing 1 (DEPDC1) biomarkers as an aid in diagnosing non-small cell lung cancer (NSCLC) mutations....
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer DEP domain containing 5 (DEPDC5) Genomewide association studies...
BioCentury | Jun 4, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) DEP domain containing 6 (DEPDC6; DEPTOR); mammalian target of rapamycin (mTOR; FRAP; RAFT1) Studies in cell culture suggest...
Items per page:
1 - 3 of 3